Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

1/2021 vol. 37
Artykuł przeglądowy

Dlaczego pacjenci nie przestrzegają zaleceń terapeutycznych?

Anna Jopowicz 1
,
Agnieszka Piechal 1, 2
,
Iwona Kurkowska-Jastrzębska 1
  1. 2nd Department of Neurology, Institute of Psychiatry and Neurology in Warsaw
  2. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Centre Preclinical Research and Technology CePT
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 75–93
Data publikacji online: 2021/11/17
Plik artykułu
06R_IPiN_FARM_2021-1C-2.pdf
  1. Al-Aqeel S, Gersuni O, Al-Sabhan J, Hilgishman M. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Cochrane Database Syst Rev 2017; 3: 1-52.
  2. Asadi-Pooya AA. Drug compliance of children and adolescents with epilepsy. Seizure 2005; 14: 393-95.
  3. Bollini P, Pampallona S, Kupelnick B, Tibaldi G, Munizza C. Improving compliance in depression: a systematic review of narrative reviews. J Clin Pharm Ther 2006; 31(3): 253-60.
  4. Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bull World Health Organ 2002; 80: 33-39.
  5. Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc 2011; 86: 304-314.
  6. Burnier M. Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence. Front Pharmacol 2019; 9: 1540.
  7. Ciebiada M, Barylski M, Górska-Ciebiada M. Ocena stopnia przestrzegania zaleceń lekarskich u starszych chorych na cukrzycę z towarzyszącymi objawami depresyjnymi. Geriatria 2017; 11: 163-170.
  8. Choi-Kwon, Kwon SU, Kim JS. Compliance with risk factor modification: early-onset versus late-onset stroke patients. Eur Neurol 2005; 54: 204-211.
  9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.
  10. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18: 527-39.
  11. Cooper C, Carpenter I, Katona C, Schroll M, Wagner C, Fialova D, Livingston G. The AdHOC Study of older adults’ adherence to medication in 11 countries. Am J Geriatr Psychiatry 2005; 13: 1067-76.
  12. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11: 44-47.
  13. Critical overview of antihypertensive therapies: what is preventing us from getting there? Based on a presentation by Mark A. Munger. Am J Manag Care 2000; 6: 4 (Suppl.): S211-S21.
  14. Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst Rev. 2020; 5(5): CD012419.
  15. Culig J, Leppe M. From Morisky to Hill-Bone; self reports scales for measuring adherence to medication. Coll Antropol 2014; 38: 55-62.
  16. De Las Cuevas C, de Leon J, Peñate W, Betancort M. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence 2017; 11: 681-690.
  17. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, Martin BC. Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc 2013; 53: 172-181.
  18. Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat 2007; 3: 117-131.
  19. FDA 2017: https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2017/207202Orig1s000TOC.cfm.
  20. Friemann K, Wciórka J. Cztery miary przestrzegania zaleceń u chorych po przebytym epizodzie psychotycznym – porównanie. Psych Pol 2013; 47(5): 759-773.
  21. Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol 2010; 105: 1495-501.
  22. Graves JW. Management of difficult-to-control hypertension. Mayo Clin Proc 2000; 75: 278-84.
  23. Guo H, He H, Jiang J. Study on the compliance of antihypertensive drugs in patients with hypertension. Chin J Epidemiol 2001; 22: 418-420.
  24. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens 2017; 35(6): 1133-1144.
  25. Harper I. Extreme condition, extreme measures? Compliance, drug resistance, and the control of tuberculosis. Anthropol Med 2010; 17: 201-14.
  26. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2001; 2: 1-50.
  27. Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A et al. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). 2005: 1-310.
  28. Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 2008; 13: 316-22.
  29. Iuga AO, McGuire MJ. Adherence and health care costs. RiskManag Healthc Policy 2014; 7: 35-44.
  30. Jimmy B, J. Patient medication adherence: measures in daily practice. Oman Med J 2011; 26: 155-9.
  31. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag 2008; 4: 269-86.
  32. Kaplan RC, Bhalodkar NC, Brown EJ Jr, White J, Brown DL. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications. Prev Med 2004; 39: 1249-55.
  33. Kardas P. Rozpowszechnienie nieprzestrzegania zaleceń terapeutycznych wśród pacjentów leczonych z powodu wybranych schorzeń przewlekłych. Pol Merk Lek 2011; XXXI(184): 215-220.
  34. Kardas P, Czeleko T, Śliwczyński A. Ciągłość i systematyczność leczenia astmy i POChP w Polsce – ocena przestrzegania zaleceń terapeutycznych na podstawie analizy krajowej bazy danych realizacji recept. Proceedings of The 10th International Conference of the Polish Pharmacoeconomics Society – ISPOR Poland Chapter, Warsaw 2012.
  35. Kini V, Ho M. Interventions to Improve Medication Adherence A Review. JAMA 2018; 320(23): 2461-2473.
  36. Kleppe M, Lacroix J, Ham J, Midden C. The development of the ProMAS: a Probabilistic Medication Adherence Scale. Patient Prefer. Adherence 2015; 9: 355-367.
  37. Kraft SA, Porter K, Wilfond BS. Research on Medical Practices and the Patient-Physician Relationship: What Can Regulators Learn from Patients? AMA J Ethics. 2015; 17(12): 1160-5.
  38. Krzysik M, Wiela-Hojeńska A. Przestrzeganie zaleceń terapeutycznych w onkologii pediatrycznej. Farm Współ 2015; 8: 1-6.
  39. Krzystanek M, Borkowski M, Skałacka K, Krysta K. A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study. Schizophr Res 2019; 204: 389-396.
  40. Kubica A, Kosobucka A, Michalski P, Fabiszak T, Felsmann M. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases. Med Res J 2017; 2(4): 115-122.
  41. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int 2015; 2015: 1-12.
  42. Lynch SS. http://ww.merckmanuals.com/home/drugs/ factors-affecting-response-to-drugs/adherence-to-drugtreatment. Merck Sharp & Dohme Corp. 2018.
  43. Manmohan T, Sreenivas G, Sastry VV, Sudha Rani E, Indira K, Ushasree T. Drug compliance and adherence to treatment. JEMDS 2012; 1: 142-159.
  44. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868-79.
  45. McGrady ME, Pai ALH. A Systematic Review of Rates, Outcomes, and Predictors of Medication Non-Adherence Among Adolescents and Young Adults with Cancer. J Adolesc Young Adul Oncol 2019; 8(5): 485-494.
  46. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
  47. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol 2012; 11: 792-802.
  48. Reid D, Abramson M, Raven J, Walters HE. Management and treatment perceptions among young adults with asthma in Melbourne: the Australian experience from the European Community Respiratory Health Survey. Respirology 2000; 5: 281-7.
  49. Saghaeiannejad-Isfahani S, Sharifi-Rad J, Raeisi A, Ehteshami A, Mirzaeian R. An evaluation of adherence to society of pharmacists’ standards care in pharmacy information systems in Iran. Indian J Pharmacol 2015; 47: 190-4.
  50. Samsonsen C, Reimers A, Bråthen G, Helde G, Brodtkorb E. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: An observational, prospective study. Epilepsia 2014; 55: e125-8.
  51. van der Sande MA, Milligan PJ, Nyan OA, Rowley JT, Banya WA, Ceesay SM et al. Blood pressure patterns and cardiovascular risk factors in rural and urban gambian communities. J Hum Hypertens 2000; 14: 489-96.
  52. Santoro E, Castelnuovo G, Zoppis I, Mauri G, Sicurello F. Social media and mobile applications in chronic disease prevention and management. Front Psychol 2015; 7: 1-3.
  53. Schumacher KR, Stringer KA, Donohue JE, Yu S, Shaver A, Caruthers RL et al. Social media methods for studying rare diseases. Pediatrics 2014; 133: e1345-353.
  54. Skóra K. Compliance, adherence, persistence – przyczyny i konsekwencje niestosowania się pacjentów do zaleceń terapeutycznych. OncoReview 2012; 2: 54-60.
  55. Steinman L, Heang H, van Pelt M, Ide N, Cui H, Rao M et al. Facilitators and Barriers to Chronic Disease Self-Management and Mobile Health Interventions for People Living With Diabetes and Hypertension in Cambodia: Qualitative Study. JMIR Mhealth Uhealth 2020; 8(4): e13536.
  56. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004; 27: 117-24.
  57. Sweileh WM, Ihbesheh MS, Jarar IS, Taha AS, Sawalha AF, Zyoud SH et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 2011; 21: 301-5.
  58. Tan X, Patel I, Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). InnovnPharm 2014; 5: 1-6.
  59. Tintoré M, Alexander M, Costello K, Duddy M, Jones DE, Law N et al. The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence 2017; 11: 33-45.
  60. Vernon A, Fielding K, Savic R, Dodd L, Nahid P. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. PLoS Med 2019; 16(12): e1002884.
  61. WHO. International League Against Epilepsy, International Bureau for Epilepsy; Atlas: Epilespy Care in the World 2005.
  62. Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc Biol Sci 2000; 267: 835-43.
  63. Wai CT, Wong ML, Ng S, Cheok A, Tan MH, Chua W et al. Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B. Aliment Pharmacol Ther 2005; 21: 1255-62.
  64. Wasilewski GJ, Milaniak I, Janik Ł, Sadowski J, Przybyłowski P. Adherence to antihypertensive therapy among heart transplant recipients. Kardiochir Torakochir Pol 2014; 11(3): 343-348.
  65. Waszyk-Nowaczyk M, Jagielska M, Simon M, Indywidualny System Dawkowania Leków jako pomoc w przestrzeganiu zaleceń terapeutycznych. Lek w Polsce 2013; 23(10): 20-26.
  66. Webb DG, Horne R, Pinching AJ. Treatment-related empowerment: preliminary evaluation of a new measure in patients with advanced HIV disease. Int J STD AIDS 2001; 12: 103-7.
  67. Winnicki M, Basiński K, Szyndler A, Chrostowska M, Narkiewicz K. Jak poprawić stopień przestrzegania zaleceń terapeutycznych i jakość współpracy lekarz–pacjent? Choroby Serca i Naczyń 2016; 13(3): 194-202.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications